APOP Stock: Why Cellect Biotechnology Is Skyrocketing Today

APOP stock holders are getting a 1:3 ratio of shares in the tie-up deal. The merger brings together Cellect's stem cell tech with Quoin's rare and orphan diseases focus. More 

Combine Cannabis and Real Estate With Innovative Industrial Properties

IIPR stock isn't a direct play on the cannabis market, nor is it the cheapest stock. Yet, it's a worthy investment in a growing industry. More 

Tesla’s China Problems Are Good News for NIO Stock

The fundamentals underlying NIO stock are strengthening significantly and rapidly, so buy shares on near-term weakness. More 

ARVL Stock: 12 Things to Know As EV Play Arrival Starts Trading Today

ARVL stock is debuting on the Nasdaq today after shareholders gave the Arrival SPAC merger the green light. Here's what to know now. More 

Amid Some Good News, The Outlook of Churchill Capital Corp IV Hasn’t Changed

Continuing to sport a huge valuation, CCIV stock still isn't worth buying after EV stocks lost momentum. More 

BowX: Run, Don’t Walk, From the WeWork IPO

WeWork lost $3.2 billion last year and now calls itself a technology platform for creating flexible workspaces. More 

Wait for Acasti Pharma Stock to Fall Further Before Buying

The future course of ACST stock depends largely on the company's lead drug candidate, CaPre. Any good news could send the shares higher. More